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I ntroduction: The use of electronic nicotine delivery systems (ENDS) such as electronic cigarettes,vapour cigarettes, and vapour/hookah pens is rapidly increasing. The effectiveness of ENDS for
smoking cessation and their safety, particularly amongst pregnant women, is largely unknown. Some
women who use tobacco products in pregnancy, such as the one described in this case study, switch to
ENDS assuming they are a safer alternative to smoking traditional cigarettes. Many obstetric providers
do not screen for ENDS use and may miss an opportunity to counsel their patients about ENDS usage,
side effects, or alternatives.
Case Description: Motivated by concern for her baby’s health, a 28-year-old patient reduced con-
sumption of traditional cigarettes and began using ENDS shortly after learning she was preg-
nant. Her obstetric team did not screen for ENDS use and was unaware that she had started us-
ing ENDS. During the postpartum period, her providers ordered a tobacco cessation consult and
the tobacco treatment specialist (TTS) discovered the patient’s ENDS use as well as her desire
to quit.
Conclusions: In the absence of consistent screening by providers and a lack of safety data re-
garding ENDS use during pregnancy, women are often given little guidance in deciphering the
potential risks and benefits of ENDS use. In this case, the patient turned to ENDS because she
thought it was safer than smoking tobacco cigarettes and was unaware that there is limited re-
search on ENDS safety. This case highlights the importance of updating clinical screening tools
to include ENDS and the need for further research investigating the safety of ENDS use during
pregnancy.
Background
Electronic nicotine delivery systems (ENDS) include many
products, such as electronic cigarettes, vapour cigarettes,
and vapour/hookah pens. ENDS use is rapidly growing
worldwide. From 2010 to 2014, the percent of Amer-
ican adults who had ever used ENDS increased from
1.8% to 12.6% and current use increased from 0.3% to
3.7% (Schoenborn & Gindi, 2015). The rate of ENDS use
amongst pregnant women is unknown, but most people
believe that ENDS are less harmful than tobacco cigarettes
in general and during pregnancy. For instance, almost
all respondents to a survey examining perceptions of the
safety of ENDS use during pregnancy indicated that to-
bacco cigarettes are definitely harmful, compared to 60%
that indicated they believed ENDS to be harmful (Baeza-
Loya et al., 2014). This belief may stem from the fact
that ENDS companies advertise that their products con-
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tain pure nicotine, similar to over-the-counter nicotine
replacement products (NRT). Research indicates that this
claim may not always be true (U.S. Food & Drug Admin-
istration, 2009).
This case describes a female patient who switched to
ENDS during pregnancy because she thought it was safer
than smoking conventional cigarettes. Her obstetric team
was unaware of this switch, so they did not discuss po-
tential risks, safety or benefits of ENDS use during preg-
nancy. Clinics providing care to pregnant women should
adapt their policies to include screening and interventions
around ENDS because the impact of ENDS use on the
mother and foetus during pregnancy remains unknown.
Even when obstetric providers are aware of a pregnant
patient’s ENDS use, it is still challenging to provide coun-
selling on this topic due to the lack of data on safety and
effectiveness of ENDS in pregnancy. Further research is
needed in this area.
Case Presentation
A 28-year-old patient presented for her first prenatal visit 
at 10-weeks gestational age. She had several complex med-
ical problems, including asthma, chronic pain, bipolar 
disorder, anxiety, depression, prior sexually transmitted 
diseases, trauma, and substance abuse. She was smoking 
1.5–2 packs per day at the outset of pregnancy. When 
her providers learned about her tobacco use, they coun-
selled her to quit completely, and she stated that she was 
interested in quitting. She declined multiple offers for a 
prescription for bupropion to assist with cessation be-
cause of concerns about taking psychiatric medications 
during pregnancy. Her prenatal notes included no sug-
gestions for obtaining behavioural cessation support and 
no discussion of her level of motivation to become com-
pletely tobacco free. Without use of additional approved 
tobacco cessation methods, she reported cutting down to 
3–5 cigarettes per day in the first trimester, and she con-
tinued to smoke cigarettes at this level for the duration of 
her pregnancy.
She delivered a healthy baby boy at 39-weeks gestation, 
and while on the postpartum floor, her providers ordered 
a consult with the Nicotine Dependence Program because 
of her continued smoking. The tobacco treatment special-
ists (TTS’s) assessment revealed that she had used ENDS 
throughout her pregnancy, and that she attributed its use 
to her success in reducing her daily cigarette consump-
tion. Prenatal notes showed no mention of ENDS, and the 
patient confirmed that no obstetric providers inquired. 
During the consult, the patient indicated that she was 
open to using NRT, especially after learning about the lack 
of data on safety and potential health risks of ENDS com-
bined with continued use of cigarettes. The TTS and the 
patient collaboratively developed a treatment plan, includ-
ing NRT, behavioural cessation strategies, social support, 
and follow-up.
Discussion
This case raises several important findings and questions. 
First, this case demonstrates the need to screen all pregnant 
women for ENDS use. A recent survey found that 40%
of obstetrician respondents do not screen for ENDS use 
(England et al., 2014). By not asking about ENDS, the 
patient’s obstetric team in this case missed the opportunity 
to counsel her regarding the potential benefits and risks of 
using these products.
Second, this case shows the potential complexity in-
volved in ENDS use during pregnancy, where ENDS was 
simultaneously used with daily tobacco cigarettes. Though 
ENDS may have initially helped her reduce the number 
of tobacco cigarettes she used during pregnancy, she re-
mained at risk for adverse pregnancy outcomes, including 
birth defects and numerous complications, by not quitting 
entirely (Suter, Mastrobattista, Sachs, & Aagaard, 2015). 
Therefore, it remains unclear whether or not the patient’s
or her baby’s health benefited by the use of ENDS as a tool
to reduce her cigarette smoking.
Third, this patient may have subjected herself and her
baby to other adverse health risks because of ENDS use,
including exposure to nicotine and other harmful con-
stituents. A recent review of the impact of nicotine on
the foetus concluded that there is no safe nicotine level
in pregnancy (Suter, Mastrobattista, Sachs, & Aagaard,
2015). The level of nicotine reported on ENDS labels is
often incorrect, so a pregnant woman who believes she
is using ENDS with a low nicotine content may actually
be exposing her foetus to high levels of nicotine (Hutzler
et al., 2014). The US Food and Drug Administration anal-
ysed various types of ENDS cartridges and found that they
contained tobacco-specific nitrosamines that may cause
cancer (U.S. Food & Drug Administration, 2009). While
no published studies have directly examined the safety
of ENDS during pregnancy, adverse health effects on a
woman and her unborn child from ENDS are a legitimate
concern.
Fourth, the patient’s providers, while offering assis-
tance with bupropion as a pharmacologic aid for cessa-
tion, did not document assistance with evidenced-based
behavioural therapies that could have helped her quit to-
bacco products entirely. For instance, psychosocial sup-
port is an effective evidenced-based treatment for preg-
nant women wishing to quit tobacco (Meernik & Gold-
stein, 2015). Other behavioural approaches could have
included case management, practical skills management,
peer support, or referral to a quitline. Such support can in-
crease cessation rates by 35%–50% compared with less in-
tensive behavioural interventions (Meernik & Goldstein,
2015).
Fifth, even if the patient’s providers knew that she
was using ENDS throughout pregnancy, it is unknown
whether they would they have suggested that ENDS is ac-
ceptable or a better alternative to smoking. A survey of
physicians found that two-thirds (67%) of the respon-
dents, including obstetric providers, believed that ENDS
may be helpful for smoking cessation, and 35% had rec-
ommended ENDS to their patients (Kandra, Ranney, Lee,
& Goldstein, 2014). This survey did not specifically ask
about recommendations to pregnant patients, which may
be lower because of the added concerns about potential
risk to the foetus; however, the responses of obstetri-
cians/gynecologists did not differ from other specialties.
An additional survey of obstetric providers found that
13.5% of respondents believed that there were no adverse
health effects associated with ENDS, and 29% thought
ENDS were safer than tobacco cigarettes (England et al.,
2014). Given these findings, it is unclear whether the pa-
tient’s providers would have encouraged her to continue
using ENDS to assist with cessation or whether they would
have advised her to quit ENDS because of unknown health
consequences.
Finally, if the patient’s providers had advised this pa-
tient to quit ENDS, would they have offered her NRT
to assist with cessation? It is unlikely that her providers
would have prescribed NRT, as she was otherwise not
offered NRT in pregnancy. This may relate to conflicting
evidence on the safety and efficacy of NRT use in pregnant
women. A systematic review concluded that there is insuf-
ficient evidence to determine whether NRT is safe or effec-
tive in pregnant women (Coleman, Chamberlain, Davey,
Cooper, & Leonardi-Bee, 2012). A recent study reported
that though single NRT was not effective, pregnant women
were successful in quitting when using combination NRT
(Brose, McEwen, & West, 2013). Though evidence on the
safety and efficacy of NRT during pregnancy is unclear
(Coleman, Chamberlain, Davey, Cooper, & Leonardi-Bee,
2012), levels of nicotine in NRT can be closely monitored
by clinicians. However, estimations of potential nicotine
and other chemical exposure from ENDS may be inaccu-
rate due to lack of standardisation in manufacturing and
labelling (Hutzler et al., 2014).
Limitations
Several limitations of this case exist. Data sources for this
case study were limited to patient self-report and prenatal
notes written by her providers. As such, some questions
were left unanswered. For example, it is unknown whether
behavioural cessation interventions and/or NRT were of-
fered after providers learned about her continued smok-
ing. It is possible that these interventions were offered,
but this effort was not documented. The patient was also
lost to follow-up, so her tobacco use status post discharge
is unknown. Another consideration involves this patient’s
multiple psychiatric comorbidities. It is well documented
that patients with co-occurring substance use and/or men-
tal health problems are offered subpar tobacco treatment
(Thorndike, Stafford, & Rigotti, 2001). This may par-
tially explain her obstetric team’s failure to screen for
ENDS use.
Conclusion
In the absence of research illustrating the impact of
ENDS use during pregnancy and appropriate screening
mechanisms for ENDS, patients are often given no guid-
ance on interpreting the risks and benefits of ENDS use.
In this case, the patient turned to ENDS because she
thought it was safer than smoking tobacco cigarettes,
and she was unaware of any potential negative health
consequences or lack of safety data regarding ENDS.
The patient’s undetected ENDS use masked her ongo-
ing tobacco use and likely interfered with her receiv-
ing the highest quality treatment, including more inten-
sive behavioural counselling. More research is needed to
guide obstetric providers in their counselling of preg-
nant ENDS users, including an urgent need to iden-
tify the safest and most effective strategies that help
pregnant women abstain from all tobacco products
and ENDS.
Learning Points
1. Medical settings must update their assessment proce-
dures to include screening for ENDS use.
2. Tobacco use during pregnancy is known to cause multi-
ple health problems. NRT should be offered to pregnant
women only after behavioural support proves ineffec-
tive. NRT use should be closely monitored by a clinician
and should be recommended before ENDS use given
the lack of regulation of ENDS and lack of evidence
regarding safety.
3. Data should be collected on the prevalence of ENDS use
amongst pregnant women, and future studies should
investigate further the safety and effectiveness of ENDS
use during pregnancy.
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